APA (7th ed.) Citation

ZJ, M., ZF, B., W, S., Q, C., T, H., MQ, L., . . . NS, X. (2022). Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Human vaccines & immunotherapeutics, 18(6), 2092363. https://doi.org/10.1080/21645515.2022.2092363

Chicago Style (17th ed.) Citation

ZJ, Mo, et al. "Safety and Immunogenicity of an Escherichia Coli-produced Bivalent Human Papillomavirus Type 6/11 Vaccine: A Dose-escalation, Randomized, Double-blind, Placebo-controlled Phase 1 Trial." Human Vaccines & Immunotherapeutics 18, no. 6 (2022): 2092363. https://doi.org/10.1080/21645515.2022.2092363.

MLA (9th ed.) Citation

ZJ, Mo, et al. "Safety and Immunogenicity of an Escherichia Coli-produced Bivalent Human Papillomavirus Type 6/11 Vaccine: A Dose-escalation, Randomized, Double-blind, Placebo-controlled Phase 1 Trial." Human Vaccines & Immunotherapeutics, vol. 18, no. 6, 2022, p. 2092363, https://doi.org/10.1080/21645515.2022.2092363.